Determinants of outcome among patients with acute liver failure listed for liver transplantation in the United States

K. Rajender Reddy, Caitlyn Ellerbe, Michael Schilsky, R. Todd Stravitz, Robert J. Fontana, Valerie Durkalski, William M. Lee, and the Acute Liver Failure Study Group – 30 September 2015 – Analyses of outcomes after acute liver failure (ALF) have typically included all ALF patients regardless of whether they were listed for liver transplantation (LT). We hypothesized that limiting analysis to listed patients might provide novel insights into factors associated with outcome, focusing attention on disease evolution after listing.

Dopamine impairs functional integrity of rat hepatocytes through nuclear factor kappa B activity modulation: An in vivo, ex vivo, and in vitro study

Cheuk‐Kwan Sun, Ying‐Hsien Kao, Po‐Huang Lee, Ming‐Chang Wu, Kun‐Cho Chen, Yu‐Chun Lin, Ming‐Shian Tsai, Po‐Han Chen – 30 September 2015 – Dopamine (DA) is commonly used to maintain the hemodynamic stability of brain‐dead donors despite its controversial effects on organ functions.

Development of hyperdynamic circulation and response to β‐blockers in compensated cirrhosis with portal hypertension

Càndid Villanueva, Agustín Albillos, Joan Genescà, Juan G. Abraldes, Jose L. Calleja, Carles Aracil, Rafael Bañares, Rosa Morillas, María Poca, Beatriz Peñas, Salvador Augustin, Joan Carles Garcia‐Pagan, Oana Pavel, Jaume Bosch – 30 September 2015 – Nonselective β‐blockers are useful to prevent bleeding in patients with cirrhosis and large varices but not to prevent the development of varices in those with compensated cirrhosis and portal hypertension (PHT). This suggests that the evolutionary stage of PHT may influence the response to β‐blockers.

Surrogate endpoints for clinical trials in primary sclerosing cholangitis: Review and results from an International PSC Study Group consensus process

Cyriel Y. Ponsioen, Roger W. Chapman, Olivier Chazouillères, Gideon M. Hirschfield, Tom H. Karlsen, Ansgar W. Lohse, Massimo Pinzani, Erik Schrumpf, Michael Trauner, Gregory J. Gores – 29 September 2015 – Primary sclerosing cholangitis (PSC) is a rare, but serious, cholestatic disease for which, to date, no effective therapy exists to halt disease progression toward end‐stage liver disease. Clinical trial design to study drugs that improve prognosis is hampered by the relatively low event rate of clinically relevant endpoints.

Subscribe to